8-K: BioAtla Announces Second Quarter 2024 Financial Results and Clinical Program Updates

BioAtla reported its Q2 2024 financial results, highlighted clinical progress, and received Fast Track Designation for ozuriftamab vedotin.

Summary

• BioAtla announced its financial results for the second quarter of 2024, with a net loss of $21.1 million, compared to a net loss of $35.8 million for the same quarter in 2023.
• Research and development expenses decreased to $16.2 million from $31.0 million in the same quarter of the previous year, primarily due to the completion of pre-clinical development for the Nectin-4 ADC and prioritization of clinical programs.
• General and administrative expenses were $5.8 million, a slight decrease from $6.2 million in the prior year's quarter.
• The company's cash and cash equivalents totaled $61.7 million as of June 30, 2024, down from $111.5 million at the end of 2023.
• BioAtla anticipates its current cash balance will fund operations through Q3 2025.
• The company's lead drug candidate, ozuriftamab vedotin, received Fast Track Designation from the FDA for the treatment of squamous cell carcinoma of the head and neck (SCCHN).
• Evalstotug, another key candidate, showed a low incidence of immune-related adverse events in both Phase 1 and 2 studies.
• Mecbotamab vedotin demonstrated a trend for improved overall survival in NSCLC patients with mutated KRAS variants.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with promising clinical data and a reduced net loss, but the significant decrease in cash reserves and the inherent risks of clinical development temper the overall sentiment.

Positives

• Ozuriftamab vedotin's Fast Track Designation could expedite its development and approval process.
• Evalstotug's favorable safety profile may enable safer combination therapies.
• Mecbotamab vedotin's positive trend in overall survival for patients with mutated KRAS variants is encouraging.
• The company's cash runway extends through Q3 2025, providing financial stability for ongoing clinical programs.
• The decrease in R&D expenses indicates improved efficiency in resource allocation.
• The net loss reduction year-over-year is a positive sign of improved financial performance.

Negatives

• The company experienced a significant decrease in cash and cash equivalents from $111.5 million at the end of 2023 to $61.7 million as of June 30, 2024.
• Net cash used in operating activities for the six months ended June 30, 2024 was $50.0 million, compared to $46.7 million for the same period in 2023.

Risks

• The company's clinical trials may face delays or not meet anticipated endpoints.
• Regulatory authorities may not be satisfied with the design or results of clinical studies.
• The company is dependent on the success of its CAB technology platform.
• The company relies on third parties for manufacturing, supply, and clinical trial conduct.
• The company may face challenges in enrolling patients in clinical trials.
• The company may not be able to form successful collaborations or partnerships.
• The company may be impacted by potential adverse impacts due to any resurgence of COVID-19 and its variants.

Future Outlook

BioAtla expects its current cash to fund operations through Q3 2025, sufficient to deliver clinical readouts, position programs for potential registrational trials, and enhance strategic collaboration discussions. The company anticipates multiple FDA meetings by year-end to discuss potential registrational trials.

Management Comments

• BioAtla continues to execute across our CAB portfolio, highlighted by ongoing positive clinical responses and a potentially differentiated safety profile observed with our CAB Phase 2 assets, said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc.
• We are pleased to receive Fast Track Designation for ozuriftamab vedotin in the treatment of recurrent or metastatic head and neck cancer and are on track to meet with the FDA this year.
• The clinical profile of evalstotug, in particular the low incidence and severity of immune-related AEs, supports a potentially best-in-class CTLA-4 antibody for the treatment of multiple solid tumors.
• Further, we are encouraged with the emerging clinical profile of mecbotamab vedotin in patients with NSCLC harboring KRAS mutation variants.

Industry Context

BioAtla's focus on conditionally active biologics (CABs) aligns with the industry trend towards developing more targeted and less toxic cancer therapies. The Fast Track Designation for ozuriftamab vedotin and the positive safety profile of evalstotug position BioAtla favorably in the competitive landscape of immuno-oncology and antibody-drug conjugates.

Comparison to Industry Standards

• The Fast Track Designation for ozuriftamab vedotin is a positive development, similar to other companies receiving expedited review for promising cancer therapies.
• Evalstotug's low incidence of immune-related adverse events is a key differentiator compared to traditional CTLA-4 inhibitors like ipilimumab and tremelimumab, which are known for higher toxicity rates.
• The observed overall survival trend with mecbotamab vedotin in KRAS-mutated NSCLC patients is competitive with other targeted therapies in this space, such as sotorasib, especially given the response in a patient who had previously failed sotorasib.
• The company's cash runway through Q3 2025 is a positive sign, but it will need to continue to manage its cash burn effectively, similar to other clinical-stage biotech companies.

Stakeholder Impact

• Shareholders may view the clinical progress and reduced net loss positively.
• Employees may be encouraged by the company's progress and financial stability.
• Patients may benefit from the development of new cancer therapies.
• Potential strategic partners may be more interested in collaborating with BioAtla due to its clinical advancements.

Next Steps

• BioAtla plans to meet with the FDA to discuss potential registrational trials for its Phase 2 programs.
• The company will present clinical data at upcoming scientific conferences, including ESMO, the Society for Melanoma Research Congress, and the Society for Immunotherapy of Cancer.
• The company will continue to enroll patients in ongoing clinical trials.
• The company will continue to advance discussions with potential strategic partners.

Key Dates

Keywords

BioAtla, CAB, Ozuriftamab vedotin, Evalstotug, Mecbotamab vedotin, Antibody-drug conjugate, Cancer therapy, Clinical trials, Fast Track Designation, ROR2, CTLA-4, AXL, NSCLC, SCCHN, KRAS, Biotechnology